Intellia Therapeutics Inc Total Assets
Intellia Therapeutics Inc total assets. Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) holds total assets worth $842.13 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NTLA market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Intellia Therapeutics Inc (2014–2025)
Total assets of Intellia Therapeutics Inc from 2014 to 2025. This chart illustrates how Intellia Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See NTLA stock price and chart for real-time trading data and today's change.
Intellia Therapeutics Inc - Asset Composition Analysis
Intellia Therapeutics Inc Total Assets Breakdown (December 2025)
Intellia Therapeutics Inc total assets breakdown as of December 2025. Intellia Therapeutics Inc's total assets of $842.13 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.5% |
| Accounts Receivable | $9.47 Million | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Intellia Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Intellia Therapeutics Inc (NTLA) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intellia Therapeutics Inc's current assets represent 62.7% of total assets in 2025, a decrease from 94.7% in 2014.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 92.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Intellia Therapeutics Inc Competitors by Total Assets
Key competitors of Intellia Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Intellia Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.08 | 5.77 | 9.90 |
| Quick Ratio | 5.08 | 5.77 | 9.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $423.83 Million | $529.01 Million | $540.38 Million |
Intellia Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Intellia Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | $842.13 Million |
| Market Capitalization | $1.40 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Intellia Therapeutics Inc's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Intellia Therapeutics Inc's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual total assets of Intellia Therapeutics Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $842.13 Million | -29.29% |
| 2024-12-31 | $1.19 Billion | -8.45% |
| 2023-12-31 | $1.30 Billion | -14.42% |
| 2022-12-31 | $1.52 Billion | +17.43% |
| 2021-12-31 | $1.29 Billion | +91.40% |
| 2020-12-31 | $676.32 Million | +102.32% |
| 2019-12-31 | $334.28 Million | -3.75% |
| 2018-12-31 | $347.31 Million | -7.69% |
| 2017-12-31 | $376.24 Million | +25.84% |
| 2016-12-31 | $298.97 Million | +263.98% |
| 2015-12-31 | $82.14 Million | +668.08% |
| 2014-12-31 | $10.69 Million | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more